Pharsight

Abilify generic

Abilify is an antipsychotic medication owned by Otsuka. This medication contains the active ingredient aripiprazole, which affects chemicals in the brain. Abilify was first authorized for market use on November 15th, 2002. The medication is available in a tablet that is taken orally.

When will Abilify generic be available?

Abilify's generic will be available after March 2nd, 2027. The last patent of Abilify, US8759350 titled 'Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders', is set to expire on this date. Therefore, generic versions of this medication can legally be produced after this date.

Abilify uses

Abilify is used in the treatment of schizophrenia and major depressive disorder (MDD). Additionally, it serves as an adjunctive treatment for MDD and acute treatment for manic and mixed episodes associated with bipolar 1 disorder. Its effectiveness is attributable to aripiprazole's action as a 5-HT1a receptor subtype agonist, which stabilizes the chemical imbalances in the brain.

Abilify patent expiration

Abilify holds several patents, with the last one, US8759350, expiring on March 2nd, 2027. After the expiration of this patent, it's possible to release the Abilify generic. Below are the details of the patent:

EPO Oppostions filed on Abilify

Litigations filed on Abilify

Abilify dosage

Want to ask something?